Skip to main content
Log in

Exposure to Solvents in Female Patients with Scleroderma

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract:

The role of exposure to solvents was investigated in female patients with connective tissue disease and Raynaud’s phenomenon using a questionnaire. Sixteen out of the 63 patients with systemic sclerosis had been exposed to solvents. A borderline significance was demonstrated compared to matched female controls (P<0.05). Fourteen out of the 66 patients with undifferentiated connective tissue disease, 18/86 of patients with Raynaud’s phenomenon, 6/45 with systemic lupus erythematosus, 1/16 with dermatopolymyositis, 1/15 with rheumatoid arthritis and 0/13 with primary Sjögren’s syndrome had been exposed to solvents. None of these groups of patients showed a statistical significance compared to matched controls. Our present findings indicate that, at least in certain areas of the world, exposure to solvents may be a provoking factor in female scleroderma, but it must be emphasised that only a borderline significance was found between the scleroderma patients and controls. A large multicenter study seems to be required to clarify the importance of solvents as provoking factors of scleroderma. Furthermore, exposure to solvents does not seem to be a provoking factor among females for the other connective tissue diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 3 January 2001 / Accepted: 18 September 2001

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Czirják, L., Kumánovics, G. Exposure to Solvents in Female Patients with Scleroderma. Clin Rheumatol 21, 114–118 (2002). https://doi.org/10.1007/PL00011216

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00011216

Navigation